4 years ago

Nuclera Secures $42.5 Million in Series B Funding to Advance Protein Printing Technology

  • Nuclera, a UK- and US-based biotech company developing benchtop protein printing technologies, has raised $42.5 million in the first close of its Series B financing

  • The funding will be used to accelerate the development and commercialization of its eProtein™ desktop bioprinter

  • The company's technology provides researchers with a streamlined way to access next-day protein supplies, and has gained traction with customers in various industries

  • The investors in the round include M&G, Amadeus Capital Partners, E Ink, RT Partners, Future Planet Capital, British Business Bank Future Fund, and G

  • K

  • Goh.

      • ProblemTechnology

      "Making proteins for research and development is expensive and slow. Current methods require large, expensive equipment and take weeks to produce proteins, slowing down research progress."

      Solution

      "Nuclera provides a desktop bioprinter that allows researchers and scientists to produce proteins on demand, in a matter of days, making research faster and more accessible."

      Covered on